Compare Danaos Corporation (DAC) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaos Corporation vs Mesoblast Limited — how do they compare? Danaos Corporation trades at $170.2 (market cap $2.99B), while Mesoblast Limited trades at $13.8 (market cap $1.81B). The key difference: Danaos Corporation is the larger of the two by market cap, and Danaos Corporation pays a 2.43% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaos Corporation for 25 Days and Mesoblast Limited for 14 Days on average.
| DAC | MESO | |
|---|---|---|
Market Cap | $2.99B | $1.81B |
Volume | 328,260 | 240,620 |
Sector | Industrials | Health |
52-Week High | $170.22 | $20.96 |
52-Week Low | $84.05 | $13.19 |
Typical Hold Time | 25 Days | 14 Days |
Enterprise Value | $2.97B | $1.89B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaos Corporation (DAC) trades at $164.48, down 0.88% on the day, with strong fundamental metrics including a low P/E of 5.57 and robust profitability margins. The stock shows a bullish technical trend, trading above key moving averages, with recent earnings consistently beating expectations. The company maintains strong cash flow generation and has declared multiple dividends, reflecting financial health and shareholder returns.
The outlook remains positive given DAC's undervaluation, earnings momentum, and dividend payments. Key risks include shipping industry cyclicality and global trade volatility. Analyst consensus is evenly split between Buy and Hold, indicating cautious optimism amid strong fundamentals and technical strength.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
